Success Metrics

Clinical Success Rate

89.7%

Based on 26 completed trials

Completion Rate

90%(26/29)

Active Trials

12(24%)

Results Posted

42%(11 trials)

Terminated

3(6%)

Phase Distribution

Ph not_applicable

31%

Ph phase_2

20%

Ph phase_3

12%

Ph phase_1

Ph phase_4

24%

Ph early_phase_1

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution49 total trials

Early Phase 1First-in-human

2(4.1%)

Phase 1Safety & dosage

3(6.1%)

Phase 2Efficacy & side effects

10(20.4%)

Phase 3Large-scale testing

6(12.2%)

Phase 4Post-market surveillance

12(24.5%)

N/ANon-phased studies

16(32.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

78.8%

26 of 33 finished

Non-Completion Rate

21.2%

7 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(13)

Completed(26)

Terminated(7)

Other(5)

Detailed Status

Completed26

Recruiting9

unknown5

Withdrawn4

Active, not recruiting3

Terminated3

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

89.7%

Most Advanced

Phase 4

Trials by Phase

Early Phase 12 (4.1%)

Phase 13 (6.1%)

Phase 210 (20.4%)

Phase 36 (12.2%)

Phase 412 (24.5%)

N/A16 (32.7%)

Trials by Status

completed2651%

withdrawn48%

recruiting918%

active_not_recruiting36%

not_yet_recruiting12%

terminated36%

unknown510%

Recent Activity

12 active trials

Showing 5 of 51

recruitingphase_2

Evaluation of the Superiority of VAsopressin Versus NOradrenaline in the Management of Patients at Risk of Kidney Failure Undergoing Cardiac Surgery With Extracorporeal Circulation

NCT05568160

View all 51 trials

Clinical Trials (51)

Showing 20 of 51 trialsScroll for more

NCT05958342Phase 2

CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial

Recruiting

NCT05738148Phase 1

Vasopressin vs. Epinephrine During Neonatal Cardiopulmonary Resuscitation

Active Not Recruiting

NCT06426407

Vasopressin Hemodynamic Response as a Septic Shock Subphenotype Indicator

Terminated

NCT02118467Phase 4

Vasoactive Drugs in Intensive Care Unit

Recruiting

NCT05568160Phase 3

Evaluation of the Superiority of VAsopressin Versus NOradrenaline in the Management of Patients at Risk of Kidney Failure Undergoing Cardiac Surgery With Extracorporeal Circulation

Active Not Recruiting

NCT06217562Phase 4

Vasopressin for Septic Shock Pragmatic Trial

Active Not Recruiting

NCT04463394Early Phase 1

The Hemodynamic Effects of Vasopressin in Patients With Fontan Physiology

Completed

NCT06547892Phase 2

Use of Vasopressin in Patients at High Risk of Acute Kidney Injury Admitted to the ICU

Recruiting

NCT06234592Not Applicable

The Effect of Vasopressor Therapy on Renal Perfusion in Septic Shock

Recruiting

NCT04501861Phase 3

Hemodynamic Effect of Norepinephrine Versus Vasopressin on the Pulmonary Circulation in Cardiac Surgery Patients:

Completed

NCT05506319Phase 4

Hypotension in the Weaning From Vasopressor Drugs

Completed

NCT06419075Phase 4

Tranexamic Acid in Vaginal Reconstructive Surgery

Withdrawn

NCT02975999Phase 2

Use of Vasopressin Following the Fontan Operation

Completed

NCT06422975

Registry of Patients in Shock Treated With Vasopressin

Recruiting

NCT06329063Not Applicable

Oral Vasopressin Modulates Neural Responses to Looming Visual Stimuli: An Eye-tracking Study

Recruiting

NCT06329037Not Applicable

The Effects of Oral Vasopressin on Attention Control: An Eye-tracking Study

Recruiting

NCT04602767Phase 4

Low Dose Vasopressin vs Phenylephrine in Cardiac Surgery

Recruiting

NCT05193370Phase 4

Angiotensin II vs. Vasopressin in Septic Shock

Withdrawn

NCT04053478Not Applicable

Effects of Ephedrine, Phenylephrine, Norepinephrine and Vasopressin on Contractility of Human Myometrium and Umbilical Vessels: An In-vitro Study

Recruiting

NCT06290596Phase 4

Vasopressin Versus Tranexamic Acid for Control of Blood Loss Related to Abdominal Hysterectomy

Not Yet Recruiting

Drug Details

Intervention Type: DRUG
Total Trials: 51